Concord Herb Powder Pharma Grade API is controlled as an active substance for incorporation into tablet, capsule, granule, and injectable finished dosage forms. Two product specifications are assigned within the product family. The oral-grade model code C-HP-PG-01 is used for blending into directly compressed tablets, wet-granulated or roller-compacted tablet formulations, hard-shell capsules, and sachet granules. The injectable-grade model code C-HP-PG-01-IG is reserved for downstream parenteral compounding and sterile filtration. The injectable grade is not a sterile API at release; it is a low-bioburden powder intended for reconstitution followed by passage through a 0.22 µm sterilizing-grade filter or aseptic incorporation into a sterile vehicle. The oral grade has a broader particle-size envelope and does not carry a bacterial endotoxin limit, while the injectable grade imposes reduced moisture, reduced bioburden, and a fine particle-size specification to support rapid dispersion and filtration.

Compendial alignment includes USP <561> for articles of botanical origin, USP <616> for bulk and tapped density, USP <786> for particle-size distribution by analytical sieving, USP <731> for loss on drying, USP <921> for water determination, USP <281> for residue on ignition, USP <61> for microbial enumeration, and USP <62> for specified pathogens. Residual solvents are assessed under USP <467>, and elemental impurities are managed under ICH Q3D with analytical procedures from USP <232>/<233>. The botanical source is controlled by macroscopic and microscopic identity testing against an authenticated voucher specimen; high-performance thin-layer chromatographic fingerprinting and marker ratio acceptance are applied as a release identity criterion.

Which Specifications Govern the Concord Herb Powder API for Oral and Injectable Manufacture?

The tabulated limits are release criteria, not in-process targets. Loss on drying is controlled by USP <731> at ≤5.0% for oral grade and ≤3.0% for injectable grade. Water content by USP <921> may be used as an alternative when residual solvent interference is absent. The powder-flow classification according to USP <1174> is usually derived from the Hausner ratio and compressibility index. A Hausner ratio above 1.35 or a compressibility index above 35.0% indicates that direct compression is not reliable; granulation is required. Residual solvents are evaluated under USP <467>; injectable grade should meet the same Class 3 threshold as oral grade unless the manufacturing route introduces Class 2 solvents, which are then controlled to the concentration limits in USP <467> Option A. The fine particle fraction for injectable grade, ≥99.0% ≤75 µm, is tighter than many botanical powders; this particle-size requirement may be produced by jet milling or controlled micronization under dry conditions. Micronization should be conducted with nitrogen inerting if the botanical powder contains oxidizable terpene or phenolic fractions.

In tablet and capsule processing, the principal failure modes are weight variation, capping, and punch filming. The material is not directly compressible at high drug loads; formulations exceeding 30.0% w/w API should be processed by wet granulation or roller compaction. Direct compression may be considered only if the final blend Hausner ratio remains below 1.35. Rotary press operation at 25–60 rpm turret speed typically requires main compression force from 8 kN to 18 kN for standard concave tooling; actual force must be set by compaction simulation or press characterization. Ejection force above 800 N suggests insufficient magnesium stearate or excessive moisture; magnesium stearate above 1.5% w/w may extend disintegration due to hydrophobic lubricant film. Tablet hardness is monitored according to USP <1217> and friability according to USP <1216>; acceptance typically requires hardness ≥4 kp and friability ≤1.0% for coated tablets. Blend uniformity and content uniformity are assessed according to USP <905>; stratified sampling of a V-blender or bin blender at 10 locations with a 1-dose unit sample size should produce RSD ≤5.0% before release to compression.

Wet granulation using aqueous binder may be performed in a high-shear granulator with impeller speed 100–200 rpm and chopper speed 1500–3000 rpm. Water addition should be stopped before the powder mass reaches the plastic limit; endpoint is preferably controlled by impeller power consumption rather than fixed water volume. Drying in a fluid-bed dryer to an outlet product temperature of 40–45°C is recommended to avoid thermal degradation of volatile marker compounds. Dry granulation by roller compaction can be used when the botanical powder shows moisture-induced stickiness or when the formulation contains heat-sensitive binders. Roller compaction specific force 8–20 kN/cm and screen milling below 800 µm are typical for preserving granule porosity and avoiding excessive fines. For hard-shell capsule filling, the granulate or powder blend should have a sieve fraction between 180 µm and 850 µm; fines below 180 µm should not exceed 15.0% to prevent segregation and dusting. Dosator-style capsule machines require a tapped density above 0.50 g/cm³ for consistent fill weight; lower bulk-density material is usually slugged or roller compacted before encapsulation. Disintegration is evaluated according to USP <701> and dissolution according to USP <711>; marker ratio acceptance is used to compensate for natural botanical constituent variation.

For granule presentations, the oral-grade powder is typically agglomerated in a fluid-bed granulator rather than compressed. A binder solution containing povidone or hydroxypropyl methylcellulose at 2.0–5.0% w/w solids is sprayed at an atomisation air pressure of 1.0–2.0 bar and inlet temperature 50–70°C. Granule growth is controlled by monitoring differential pressure across the filter and outlet humidity; over-wetting produces massing and wall deposition. The dried granules are sieved through 1.0 mm and retained on 180 µm to limit both oversize and fines. Sachet filling on a vertical form-fill-seal machine requires a granule bulk density above 0.45 g/cm³ and a flow through a 10 mm orifice of ≥10 g/s to maintain fill-weight variation ≤±5.0%. Hygroscopic granule formulations should be packaged with a desiccant sachet if the moisture content exceeds 3.0% or if the product is stored at relative humidity above 60% RH.

When Injectable-Grade Material Is Selected Over Oral-Grade Material

Injectable-grade Concord Herb Powder API C-HP-PG-01-IG is used only when the finished dosage form is intended for parenteral administration or when the manufacturing train includes a validated sterilizing filtration step. The injectable grade is supplied with a bioburden specification of ≤10² CFU/g, compared with the oral-grade total aerobic microbial count of ≤10³ CFU/g. This tighter bioburden is not a sterility guarantee; sterility testing per USP <71> is performed on the final filtered or aseptically filled product, not on the API powder. Bacterial endotoxin control follows USP <85>; if the maximum intravenous dose is not established, the product is released with an endotoxin limit of ≤0.25 EU/mg. When the clinical dose is known, the limit is calculated as K/M per USP <85>, where K is 5 EU/kg for intravenous or 0.2 EU/kg for intrathecal administration and M is the maximum dose per kilogram. The injectable grade must also be controlled for sub-visible particulate matter in the reconstituted solution per USP <788>; this is a property of the complete formulation, not an API release test.

Reconstitution of C-HP-PG-01-IG should be performed in Water for Injection at 20–25°C with gentle magnetic stirring at 100–200 rpm for 5–15 min. High-shear homogenization is avoided because it can introduce gas bubbles and shear-induced agglomeration of hydrophobic surface components. The powder should be wetted slowly into the vortex; adding the entire charge at once may form a hydrated gel layer around the particle core and slow dissolution. After reconstitution, the solution or suspension is passed through a 0.22 µm polyethersulfone or polyvinylidene fluoride membrane. Cellulose acetate filters may be incompatible with some botanical polyphenolic fractions; filter compatibility studies must be performed per FDA 21 CFR 211.84 or equivalent. Terminal sterilization by moist heat is not recommended for the botanical matrix because steam at 121°C for 15 min may degrade heat-sensitive ester, phenolic, or terpenic constituents and produce visible precipitate. Aseptic filtration remains the primary processing route. The injectable grade is not suitable for dry-heat sterilization above 160°C due to charring. Chemical incompatibility is observed with strong oxidising acids and alkaline hydrolysis; the botanical polyphenol fraction may darken and form insoluble adducts at pH above 8.0. Formulation pH should be kept between 4.0 and 7.0 unless stability data support otherwise. Storage should be in sealed, desiccated containers under ≤30% RH to limit moisture uptake and microbial proliferation.

Compared with botanical raw material traded as simple powder, Concord Herb Powder Pharma Grade API is released as an active substance under current good manufacturing practice for active pharmaceutical ingredients. Crude botanical powder may carry no particle-size distribution, no validated microbial specification, and no elemental impurity data. The API adds USP <561> identity, USP <616> density, USP <786> size control, and ICH Q3D elemental impurity risk management. The product also differs from solvent-extracted dry extracts, which often contain maltodextrin or silicon dioxide carriers and may have altered native botanical constituent ratios due to extraction selectivity. Because Concord Herb Powder retains the native water-washed and milled botanical matrix, the insoluble fiber and protein fractions remain present; this influences tablet compression and dissolution. The product is therefore not a drop-in replacement for a concentrated dry extract in a formula already optimized for extract-based tablets. Conversely, it is not substituted for crude powder in tea or supplement blends without a deliberate pharmaceutical development programme. Published data for this specific configuration is limited.

Comparative Differentiation Against Crude Botanical Powders and Dry Extracts

The comparison indicates that Concord Herb Powder API is positioned as a controlled active substance rather than a commodity botanical powder. The presence of native cellulosic matrix in the powder increases disintegration time relative to highly soluble dry extracts; dissolution method development should use a discriminating medium based on marker solubility, not sink conditions alone. In capsule products, the bulk density specification of 0.35–0.55 g/cm³ is intentionally wider than dry extract to allow filling after granulation; direct encapsulation of unprocessed API may result in fill-weight variability if tapped density falls below 0.50 g/cm³. For injection, no dry extract or crude powder can be considered equivalent without meeting the same low-bioburden and endotoxin specifications, and this route requires injectable-grade C-HP-PG-01-IG. Residue on ignition at ≤1.0% indicates low mineral content but does not replace elemental impurity testing by USP <232>/<233>; a lot-specific elemental profile should be available in the vendor qualification file.